Resources

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

Chris Molloy on new pension scale-up fund news, member news from Touchlight, the major GSK investment in Cambridge, a valuable collaboration for Relation and BIA's parliamentary engagement

Biosolutions are a billion-pound national asset delivering growth in every region of the UK

Find out more about a free, independent review of R&D tax claims for BIA members.

Touchlight announced the first UK patient was dosed with a bespoke cancer vaccine manufactured using its proprietary dbDNA technology.

Up to $110 million upfront and success-based milestones collaboration will generate large-scale human cellular perturbation datasets to advance understanding of disease biology.

TauRx gathered representatives from leading patient advocacy groups including Alzheimer Europe, Alzheimer Scotland and Alzheimer's Disease International to Scotland House in London.

Chris Molloy on what the new Government means for the sector, a farewell to Lord Patrick Vallance, gene synthesis screening and TechBio UK early bird tickets

Moa Technology announces a £22.2 million Series C financing round

Pioneer Group has announced the launch of new regional accelerator programmes designed to support early-stage life science and tech companies accelerate their journey to market.

ELRIG has appointed Drs Hitesh Sanganee and Marcus Schindler to its Scientific Advisory Board (SAB).

Lonza and Engitix announced a licensing agreement to advance the development of antibody-drug conjugates (ADCs).

tranScrip recently hosted its Ask the Experts Live Q&A: From Preclinical to First-in-Human. If you couldn't join us live, the full recording is now available to watch on demand at your convenience.

From first-in-class approvals to billion-dollar deals, Q2 2026 signals a new era for antibody innovation

eXmoor Pharma and Evox Therapeutics announce the successful completion of a technology transfer programme for Evox’s exosome-enabled gene editing technology.

Chris Molloy on the Q2 2026 finance report, investment in Draig Therapeutics, MHRA meeting, centure capital summit and upcoming BIA events

Theolytics has relocated to ARC Oxford, taking 5,500 SQF at the growing innovation campus.

UK biotech financing hit a five-year high in the second quarter of 2026, with total equity financing reaching £2.11 billion, including a record £2.05 billion in venture capital.